ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR039

Vitamin D3 Repletion Improves Vascular Function, as Measured by Full-Length Osteopontin, in a High-Risk African American Cohort

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Nicholas, Susanne B., UCLA Medical Center, Los Angeles, California, United States
  • Sinha, Satyesh K., Charles R Drew University of Medicine and Science, Los Angeles, California, United States
  • Sun, Ling, Xuzhou Central Hospital, Xuzhou, China
  • Didero, Michelle, University of California, Los Angeles, Los Angeles, California, United States
  • Lee, Jae eun, Jackson State Univerity, Madison, Mississippi, United States
  • Meng, Yuan-Xiang, Morehouse School of Medicine, East Point, Georgia, United States
  • Sung, Jung hye, Jackson State University, Jackson, Mississippi, United States
  • Norris, Keith C., UCLA, Marina Del Rey, California, United States

Vitamin D deficiency is common among patients with chronic kidney disease (CKD). African Americans (AAs) suffer disproportionately fromCKD and cardiovascular (CV) disease, and 80% of AAs are vitamin D deficient. The effects of vitamin D on vascular and renal health in patients with CKD have been contradictory, in part due to different study designs.Hence, the impact of vitamin D therapy on CV health in CKD patients, especially AAs is unknown. We examined the effect of vitamin D supplement on the cardio-renal biomarkers: full-length osteopontin (flOPN), c-terminal fibroblast growth factor-23 (cFGF23), and plasminogen activator inhibitor-1 (PAI-1), which have been implicated in the pathology of both vascular and renal function in CKD.


We performed a randomized, placebo-controlled study of high-risk, overweight AAs with controlled hypertension, normal renal function and vitamin D deficiency, treated with 100,000 IU vitamin D3 (N=65) or placebo (N=65) every 4 weeks for 12 weeks. We measured renal function (CKD-EPI eGFR, urinary albumin-to-creatinine ratio (ACR)), and quantified plasma cFGF23, PAI-1 and flOPN by ELISA, vascular function (pulse wave velocity (PWV), augmentation index, waist circumference (WC), and 24h-ambulatory blood pressure (BP)). We performed multiple regression controlling for the placebo-treated group to understand the relationship between the log values of flOPN, cFGF23, and PAI-1 with cardiovascular and renal risk factors.


Compared to placebo vitamin D3 repletion did not change eGFR and BP values. Vitamin D3 levels increased 2-fold (p<0.0001) and iPTH levels decreased 13% (p=0.007) with repletion, which was associated with a 10% reduction in log-flOPN levels (p=0.03). There were no significant changes in log-cFGF23 or log-PAI-1 with vitamin D3 repletion. Multiple regression analysis indicated that flOPN was associated with reduced PWV (p=0.04) and diastolic BP (p=0.02), while cFGF-23 was associated only with reduced diastolic BP (p=0.05), and a trend for increased eGFR (p=0.06).


Vitamin D3 repletion may improve vascular function in a subset of AAs with controlled hypertension and vitamin D3 deficiency. Compared to cFGF-23 and PAI-1, flOPN may be a more sensitive vascular function biomarker in this population.


  • Other NIH Support